BPC-157: Mechanism, Published Studies and Recovery Applications
The most-studied gastric body peptide in animal models of tissue repair.
What is BPC-157
BPC-157 (Body Protection Compound), 15-amino-acid synthetic peptide from gastric juice protein. Sikiric, 1990s.
Mechanism
- Angiogenesis via VEGFR2.
- Nitric oxide pathway.
- FGF/EGF activation.
- Brain-gut axis.
Key studies
Tendon
Achilles transection: faster collagen organization at 4–6 wk.
Intestine
DSS colitis: reduced ulceration.
Bone
Denser callus at 4 weeks.
Dose ranges
Animal: 10–250 mcg/kg/day. Human self-reported: 250–500 mcg twice daily SC. Descriptive context only.
TB-500 synergy
BPC-157 (angiogenesis) + TB-500 (cell migration) = Wolverine Stack.
vs alternatives
- BPC-157: systemic angiogenesis.
- GHK-Cu: dermal matrix.
- KPV: cutaneous anti-inflammatory.
Related products
Bakri: BPC-157 has no identified receptor and only two human trials exist (rectal, in ulcerative colitis, with unpublished data). Its angiogenesis pathway (VEGF) is the same one tumors use, so Huberman avoids it without an active injury. Nearly all evidence is from animal models.
Educational context (RUO). Based on “Peptides: The Science, Uses & Safety” (Huberman Lab, Jun 2026). Not an endorsement by Dr. Bakri or Dr. Huberman. Watch the episode⚠ Research use only. Not medical advice.